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Abstract: 42 
 43 
The immunological synapse allows antigen presenting cells (APC) to convey a wide array of 44 
functionally distinct signals to T cells, which ultimately shape the immune response. The relative 45 
effect of stimulatory and inhibitory signals is influenced by the activation state of the APC, 46 
which is determined by an interplay between signal transduction and metabolic pathways. While 47 
toll-like receptor ligation relies on glycolytic metabolism for the proper expression of 48 
inflammatory mediators, little is known about the metabolic dependencies of other critical 49 
signals such as interferon gamma (IFNg). Using CRISPR-Cas9, we performed a series of 50 
genome-wide knockout screens in macrophages to identify the regulators of IFNg-inducible T 51 
cell stimulatory or inhibitory proteins MHCII, CD40, and PD-L1. Our multi-screen approach 52 
enabled us to identify novel pathways that control these functionally distinct markers. Further 53 
integration of these screening data implicated complex I of the mitochondrial respiratory chain in 54 
the expression of all three markers, and by extension the IFNg signaling pathway. We report that 55 
the IFNg response requires mitochondrial respiration, and APCs are unable to activate T cells 56 
upon genetic or chemical inhibition of complex I. These findings suggest a dichotomous 57 
metabolic dependency between IFNg and toll-like receptor signaling, implicating mitochondrial 58 
function as a fulcrum of innate immunity.  59 
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Introduction: 65 
During the initiation of an adaptive immune response, the antigen presenting cell (APC) serves 66 
as an integration point where tissue-derived signals are conveyed to T cells. Myeloid APCs, such 67 
as macrophages and dendritic cells (DCs), are responsible for the display of specific peptides in 68 
complex with MHC molecules, and for the expression of co-signaling factors that tune the T cell 69 
response (1). The expression of stimulatory or inhibitory co-signaling molecules depends on the 70 
local immune environment and activation state of the APC (2). In particular, interferon gamma 71 
(IFNg) stimulates the surface expression of MHC proteins (3-9), co-stimulatory proteins such as 72 
CD40, and the secretion of cytokines like IL-12 and IL-18 (10), to promote T cell activation and 73 
the production of IFNg-producing T-helper type 1 (Th1) effector cells (11-15). In the context of 74 
local inflammation, pattern recognition receptor (PRR) ligands and endogenous immune 75 
activators can collaborate with IFNg to induce the expression of co-inhibitory molecules, like 76 
programmed death-ligand 1 (PD-L1) (16-22), which ligates T cell programmed death receptor 1 77 
(PD1) to limit immune activation and mitigate T cell-mediated tissue damage (23-26).  78 
 79 
IFNg mediates these complex effects via binding to a heterodimeric surface receptor (27-80 
30). The subunits of the complex, IFNGR1 and IFNGR2, assemble once IFNGR1 is bound by its 81 
ligand (31, 32). Complex assembly promotes the phosphorylation of janus kinases 1 and 2 (JAK1 82 
and JAK2) followed by activation of the signal transducer and activation of transcription 1 83 
(STAT1) (33). Phosphorylated STAT1 then dimerizes and translocates to the nucleus to activate 84 
the transcription of genes containing promoters with IFNg-activated sequences (GAS), which 85 
includes other transcription factors such as interferon regulatory factor 1 (Irf1) that amplify the 86 
expression of a large regulon that includes T cell co-signaling molecules (34, 35). The 87 
.CC-BY-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.22.393538doi: bioRxiv preprint 
importance of this signaling pathway is evident in a variety of diseases including cancer (36-40), 88 
autoimmunity (41, 42), and infection (43). Individuals with inborn deficiencies in IFNg 89 
signaling, including mutations to the receptor (44, 45), suffer from a defect in Th1 immunity that 90 
results in an immunodeficiency termed Mendelian susceptibility to mycobacterial disease 91 
(MSMD) (46-49). Conversely, antagonists of IFNg-inducible inhibitory molecules, such as PD-92 
L1, are the basis for checkpoint inhibitor therapies that effectively promote T cell-mediated 93 
tumor destruction (26, 28, 50-55).  While the obligate components of the IFNg signaling pathway 94 
are well known, characterization of additional regulators of this response promises to identify 95 
both additional causes of immune dysfunction and new therapeutic targets. 96 
 97 
Recent data suggests that cellular metabolism is an important modulator of the APC-T 98 
cell interaction. In particular, microbial stimulation of PRR receptors on the APC induces 99 
glycolytic metabolism and this shift in catabolic activity is essential for cellular activation, 100 
migration, and CD4+ and CD8+ T cell activation (18, 56-70). The metabolic state of the T cell is 101 
also influenced by the local environment and determines both effector function and long-term 102 
differentiation into memory cells (71, 72).  Like PRR signaling, IFNg stimulation has been 103 
reported to stimulate glycolysis and modulate cellular metabolism in macrophages (66, 73).  104 
However, the effects of different metabolic states on IFNg-stimulated APC function remains 105 
unclear.  106 
 107 
To globally understand the cellular pathways that influence IFNg-dependent APC 108 
function, we used a CRISPR-Cas9 knockout library (74) in macrophages to perform a series of 109 
parallel forward-genetic screens for regulators of three IFNg-inducible co-signaling molecules: 110 
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MHCII, CD40, and PD-L1. We identified positive and negative regulators that controlled each 111 
marker, underscoring the complex regulatory networks that influence the interactions between 112 
APCs and T cells. Pooled analysis of the screens uncovered shared regulators that contribute to 113 
the global IFNg response. Prominent among these general regulators was complex I of the 114 
respiratory chain. We report that the activity of the IFNg receptor complex and subsequent 115 
transcriptional activation depends on mitochondrial function in both mouse and human myeloid 116 
cells. Experimental perturbation of respiration inhibits the capacity of both macrophages and 117 
dendritic cells to stimulate T cells, identifying mitochondrial function as a central point where 118 




Forward genetic screen identifies regulators of IFNg-inducible MHCII, CD40 and PD-L1 123 
cell surface expression. 124 
 125 
To investigate the diverse regulatory pathways underlying the IFNg response, we 126 
examined the expression of three functionally distinct cell surface markers that are induced by 127 
IFNg. Stimulation of Cas9-expressing immortalized bone marrow-derived macrophages with 128 
IFNg for 24 hours resulted in the upregulation of T cell stimulatory molecules, major 129 
histocompatibility complex class II (MHCII) and CD40, and the inhibitory ligand PD-L1 130 
(Cd274), on the cell surface (Figure 1A). To identify genes that regulate the expression of these 131 
markers, Cas9-expressing macrophages were transduced with a lentiviral genome-wide knockout 132 
(KO) library containing four single guide RNAs (sgRNAs) per protein-coding gene and 1000 133 
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non-targeting control (NTC) sgRNAs (74). The knockout library was then stimulated with IFNg, 134 
and fluorescently activated cell sorting (FACS) was used to select for mutants with high or low 135 
cell surface expression of each individual marker (Figure 1B). For each of the three surface 136 
markers, positive and negative selections were performed in duplicate. The sgRNAs contained in 137 
the input library and each sorted population were amplified and sequenced (Figure 1A,B).  138 
To estimate the strength of selection on individual mutant cells, we specifically assessed 139 
the relative abundance of cells harboring sgRNAs that target each of the surface markers that 140 
were the basis for cell sorting. When the abundances of sgRNAs specific for H2-Ab1 (encoding 141 
the MHCII, H2-I-A beta chain), Cd40, or Cd274 (PD-L1) were compared between high- and 142 
low-expressing cell populations, we found that each of these sgRNAs were significantly depleted 143 
from the cell populations expressing the targeted surface molecule, while each had no consistent 144 
effect on the expression of non-targeted genes (Figure 1C). While not all individual sgRNAs 145 
produced an identical effect, we found that targeting the genes that served as the basis of sorting 146 
altered the mean relative abundance 30-60 fold, demonstrating that all selections efficiently 147 
differentiated responsive from non-responsive cells.  148 
We next tested for statistical enrichment of sgRNAs using MAGeCK-MLE (75), which 149 
employs a generalized linear model to identify genes, and by extension regulatory mechanisms, 150 
controlling the expression of each surface marker. This analysis correctly identified the 151 
differential representation of sgRNAs targeting genes for the respective surface marker in the 152 
sorted populations in each screen, which were found in the top 20 ranked negative selection 153 
scores (Ranks: H2-Ab1 = 20, Cd40 = 1, Cd274 = 3; Table S1). Upon unsupervised clustering of 154 
b scores for the most highly enriched genes in each screen (top 5%, positive or negative) both 155 
common and pathway-specific effects were apparent (Figure 1D; Table S2). A small number of 156 
.CC-BY-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.22.393538doi: bioRxiv preprint 
genes assigned to Cluster 1, including the IFNg receptor components (Ifngr1 and Ifngr2), were 157 
strongly selected in the non-responsive population in all three selections. However, many 158 
mutations appeared to preferentially affect the expression of individual surface markers, 159 
including a number of known pathway-specific functions. For example, genes previously shown 160 
to specifically control MHCII transcription, such as Ciita, Rfx5, Rfxap, Rfxank, and Creb1 (8, 76-161 
78) were found in Cluster 4 along with several novel regulators that appear to be specifically 162 
required for this pathway. MHCII-specific factors are reported in an accompanying study (79).  163 
Genes specifically required for CD40 expression in Cluster 3 included the heterodimeric 164 
receptor for TNF.  Tnfrsf1a and Tnfrsf1b were the 6th and 50th lowest b scores in the CD40 165 
screen, respectively.  Previous studies suggested that TNF stimulation enhances IFNg-mediated 166 
CD40 expression in hematopoietic progenitors (80), and we confirmed this observation in 167 
macrophages (Figure 1E). We observed a 6-fold higher induction of CD40 in macrophages 168 
stimulated with a combination of IFNg and TNF compared to IFNg alone. This synergy was 169 
specific to CD40 induction, as we did not observe any enhancement of IFNg-induced MHCII 170 
expression by TNF addition.  171 
Several recent studies identified genes that control PD-L1 expression in cancer cell 172 
lines(28, 53, 55, 81-86), and we validated the PD-L1-associated clusters using these candidates. 173 
Our analysis found the previously-described negative regulators, Irf2 (87), Keap1, and Cul3 (88-174 
90) in the PD-L1-related Cluster 7, along with novel putative negative regulators such as the 175 
oligosaccharlytransferase complex subunit Ostc and the transcriptional regulator, Cnbp. We 176 
generated knockout macrophages for each of these novel candidates and confirmed that mutation 177 
of these genes enhances the IFNg-dependent induction of PD-L1 surface levels (Figure 1F). 178 
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Cumulatively, these data delineate the complex regulatory networks that shape the IFNg 179 
response.  180 
 181 
Mitochondrial complex I is a positive regulator of the IFNg response. 182 
To identify global regulators of the IFNg response, we performed a combined analysis, 183 
reasoning that treating each independent selection as a replicate measurement would increase our 184 
power to identify novel pathways. We used MAGeCK to calculate a selection coefficient (b) for 185 
each gene by maximum likelihood estimation (75). By combining the 24 available measurements 186 
for each gene (three different markers, each selection in duplicate, and four sgRNAs per gene), 187 
we found that the resulting selection coefficient reflected the global importance of a gene for the 188 
IFNg response (Table S3). The most important positive regulators corresponded to the proximal 189 
IFNg signaling complex (Figure 2A). Similarly, we identified known negative regulators of IFNg 190 
signaling, including the protein inhibitor of activated Stat1 (Pias1) (91), protein tyrosine 191 
phosphatase non-receptor type 2 (Ptpn2) (84), Mitogen activate protein kinase 1 (Mapk1), and 192 
suppressor of cytokine signaling 1 (Socs1) and 3 (Socs3). 193 
We performed gene set enrichment analysis (GSEA) using a ranked list of positive 194 
regulators from the combined analysis (Table S4) (92). Among the top enriched pathways was a 195 
gene set associated with type II interferon (e.g., IFNg) signaling (normalized enrichment score = 196 
2.45, q-value = 7.98e-5), validating the approach. GSEA identified a similarly robust enrichment 197 
for gene sets related to mitochondrial respiration and oxidative phosphorylation (Figure 2B). In 198 
particular, we found a significant enrichment of gene sets dedicated to the assembly and function 199 
of the NADH:ubiquinone oxidoreductose (hereafter, “complex I”) of the mitochondrial 200 
respiratory chain. Complex I couples electron transport with NADH oxidation and is one of four 201 
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protein complexes that comprise the electron transport chain (ETC) that generates the 202 
electrochemical gradient for ATP biosynthesis. To confirm the GSEA results, we examined the 203 
combined dataset for individual genes that make up each complex of the ETC (Figure 2C). This 204 
analysis demonstrated that sgRNAs targeting components of complexes II, III or IV had minimal 205 
effects on the expression of the IFNg-inducible surface markers tested. In contrast, the disruption 206 
of almost every subunit of complex I impaired the response to IFNg, with the notable exception 207 
of Ndufab1. As this gene is essential for viability (93), we assume that cells carrying Ndufab1 208 
sgRNAs retain functional target protein. 209 
To investigate the contribution of specific complex I components to different IFNg-210 
stimulated phenotypes, we reviewed the surface marker-specific enrichment scores for genes that 211 
contribute to the complex assembly, the electron-accepting N-module, or the electron-donating Q 212 
module (93-98). Of the 48 individual assembly factors or structural subunits of complex I present 213 
in our mutant library, 29 were significantly enriched as positive regulators in the global analysis 214 
and were generally required for the induction of all IFNg-inducible markers (Fig. 2D). The 215 
enrichment for each functional module in non-responsive cells was statistically significant. 216 
However, not all individual complex I components were equally enriched, which could reflect 217 
either differential editing efficiency or distinct impacts on function. To investigate the latter 218 
hypothesis, we compared our genetic data with a previous proteomic study that quantified the 219 
effect of individual complex I subunits on the stability of the largest subcomplex, the N-module 220 
(93). For a given subunit, we found a significant correlation between the magnitude of 221 
enrichment in our genetic screen and its effect on the structural stability of the module (Fig. 2E), 222 
specifically implicating the activity of complex I in the IFNg response.  223 
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To directly test the predictions of the screening data, we used CRISPR to generate 224 
individual macrophage lines that were deficient for complex I subunits. We first validated the 225 
expected metabolic effects of complex I disruption by comparing the intracellular ATP levels in 226 
macrophages carrying non-targeting control sgRNA (sgNTC) with sgNdufa1 and sgNdufa2 lines. 227 
When cultured in media containing the glycolytic substrate, glucose, all cell lines produced 228 
equivalent amounts of ATP (Figure 3A). However, when pyruvate was provided as the sole 229 
carbon source, and ATP generation depends entirely upon flux through ETC and oxidative 230 
phosphorylation (OXPHOS),  both sgNdufa1 and sgNdufa2 macrophages contained decreased 231 
ATP levels compared to sgNTC cells (Figure 3B). To confirm the glycolytic dependency of 232 
complex I mutant macrophages, we grew cells in complete media with glucose and treated with 233 
the ATP synthase (complex V) inhibitor, oligomycin, which blocks ATP generation by 234 
OXPHOS. While oligomycin reduced ATP levels in sgNTC macrophages, this treatment had no 235 
effect in sgNdufa1 and sgNdufa2 cells (Supplementary Figure 1A), confirming that these 236 
complex I-deficient cells rely on glycolysis for energy generation. IFNg treatment slightly 237 
reduced ATP levels in glucose containing media but did not differentially affect cell lines (Figure 238 
3A). Throughout these experiments we found that the sgNdufa1 mutant showed a greater 239 
OXPHOS deficiency than the sgNdufa2 line.  240 
We next compared the response to IFNg in macrophages lacking Ndufa1 and Ndufa2 with 241 
those carrying CRISPR-edited alleles of Ifngr1 or the negative regulator of signaling, Ptpn2. As 242 
CD40 was found to rely on more complex inputs for expression, which include TNF (Figure 1E), 243 
we relied on MHCII and PD-L1 as markers of the IFNg response for subsequent studies. As 244 
expected, and consistent with the genetic screen, we found that the loss of Ifngr1 or Ptpn2 either 245 
abrogated or enhanced the response to IFNg, respectively. Also consistent with predictions, 246 
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mutation of complex I genes significantly reduced the IFNg-dependent induction of MHCII and 247 
PD-L1 compared to sgNTC (Figure 3C-F). The Ndufa1 mutation that abrogates OXPHOS, 248 
reduced MHCII induction to the same level as Ifngr1-deficient cells. To confirm these results 249 
using an orthologous method we treated cells with the complex I inhibitor, rotenone (99). This 250 
treatment caused a dose-dependent inhibition of the IFNg-induced MHCII expression in sgNTC 251 
macrophages (Figure 3G) and had a similar inhibitory effect on the residual IFNg response in 252 
Ndufa2-deficient cells. Together these results confirm that complex I is required for the induction 253 
of immunomodulatory surface molecules in response to IFNg.  254 
To investigate what aspect of mitochondrial respiration contributes to the IFNg response, 255 
we inhibited different components of the ETC. All inhibitors were used at a concentration that 256 
abrogated OXPHOS-dependent ATP generation (Supplementary Figure 1B). The complex V 257 
inhibitor, oligomycin, inhibited the IFNg-induced MHCII expression, albeit to a lesser extent 258 
than direct complex I inhibition with rotenone (Figure 3H). This partial effect could reflect an 259 
inability to dissipate the proton motive force (PMF), which inhibits electron flux throughout the 260 
ETC, including through complex I (100). Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) 261 
disrupts mitochondrial membrane potential and OXPHOS while preserving electron flux. CCCP 262 
had no effect on the IFNg response, indicating that ATP generation is dispensable for 263 
IFNg responsiveness and highlighting a specific role for complex I activity.  264 
 We then altered the media composition to test the sufficiency of mitochondrial respiration 265 
to drive IFNg responses independently from aerobic glycolysis. IFNg was found to stimulate 266 
MHCII expression to a similar degree in macrophages cultured in complete media with glucose 267 
as in media containing only pyruvate or citrate, which must be catabolized via mitochondrial 268 
respiration (Figure 3H). Inhibition of mitochondrial pyruvate import with the chemical inhibitor, 269 
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UK5099 (101), abrogated MHCII induction in cultures grown in pyruvate, but not in citrate, 270 
which is imported via a UK5099-independent mechanism. Taken together these results suggest 271 
that cellular respiration is both necessary and sufficient for maximal expression of the IFNg-272 
inducible surface markers MHCII and PD-L1.    273 
 274 
Mitochondrial function is specifically required IFNg-dependent responses. 275 
The mitochondrial-dependency of the IFNg response contrasted with the known 276 
glycolytic-dependency of Toll-like receptor (TLR) signaling, suggesting that TLR responses 277 
would remain intact when complex I was inhibited. Indeed, not only were TLR responses intact 278 
in sgNdufa1 and sgNdufa2 mutant macrophages, these cells secreted larger amounts of TNF or 279 
IL-6 than sgNTC cells in response to the TLR2 ligand, Pam3CSK4. (Figure 4A).  Thus, the 280 
glycolytic dependency of these cells enhanced the TLR2 response, indicating opposing metabolic 281 
dependencies for IFNg and TLR signaling. 282 
Whether the effects of complex I on macrophage responsiveness was the result of 283 
reduced mitochondrial respiratory function or secondary to cellular stress responses, such as 284 
radical generation, remained unclear. To more directly relate mitochondrial function to these 285 
signaling pathways, we created cell lines with reduced mitochondrial mass. Macrophages were 286 
continuously cultured in linezolid (LZD), an oxazolidinone antibiotic that inhibits the 287 
mitochondrial ribosome (102-104). This treatment produced a cell line with ~50% fewer 288 
mitochondrial genomes per nuclear genome and a corresponding decrease in OXPHOS capacity, 289 
compared to control cells grown in the absence of LZD (Figure 4B,C). Cells were cultured 290 
without LZD for 16 hours and then stimulated with either IFNg or Pam3CSK4. Consistent with 291 
our complex I inhibition studies, we found this reduction in mitochondrial mass nearly abrogated 292 
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the IFNg-dependent induction of MHCII (Figure 4D), while the TLR2-dependent secretion of 293 
TNF and IL-6 was preserved or enhanced (Figure 4E and 4F). Thus, mitochondrial activity, 294 
itself, is necessary for a robust IFNg response.  295 
To further address potential secondary effects of mitochondrial inhibition on the 296 
IFNg response, we investigated the role of known oxygen or nitrogen radical-dependent 297 
regulators (Supplementary Figure 1C-G). Inhibition of ROS generation by replacing glucose 298 
with galactose (66, 100, 105) had no effect on IFNg-induced MHCII induction.  Similarly, 299 
neutralization of cytosolic or mitochondrial radicals with N-acetylcysteine or MitoTempo, 300 
respectively, had no effect on MHCII induction either alone or in combination with ETC 301 
inhibition. The role of the cytosolic redox sensor, HIF1a (106, 107) was addressed by 302 
chemically stabilizing this factor with dimethyloxalylglycine (DMOG). A potential role for nitric 303 
oxide production was addressed with the specific NOS2 inhibitor 1400W (60, 66, 108). Neither 304 
of these treatments affected IFNg-induced MHCII cell surface expression in the presence or 305 
absence of simultaneous Pam3CSK4, further supporting a direct relationship between 306 
mitochondrial respiratory capacity and the IFNg response. 307 
 308 
Complex I is specifically required for IFNg signaling in human cells. 309 
 To understand the function of complex I during IFNg-stimulation in human cells, we used 310 
monocyte-derived macrophages (MDM) from peripheral blood of healthy donors. As in our 311 
mouse studies, we assessed the response of these cells to IFNg or Pam3CSK4 by quantifying the 312 
abundance of IFNg-inducible surface markers or cytokines that were optimized for human cells. 313 
Since HLA-DR is not strongly induced by IFNg, we included ICAM1 in addition to CD40 and 314 
PD-L1 as surface markers. As seen in the murine model, rotenone inhibited the IFNg-mediated 315 
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induction of all three markers (Figure 5A). TLR2 responses were assessed by the production of 316 
TNF and IL-1b. Upon Pam3CSK4 stimulation, rotenone significantly enhanced the secretion of 317 
IL-1b and TNF (Figure 5B). While simultaneous treatment with both IFNg and Pam3CSK4 318 
produced the previously described inhibition of IL-1b (109), rotenone still did not decrease the 319 
production of these TLR2 dependent cytokines. Thus, as we observed in mouse cells, complex I 320 
is specifically required for IFNg signaling in human macrophages.  321 
 322 
Complex I inhibition reduces IFNg receptor activity.  323 
To understand how complex I activity was shaping the IFNg response, we first 324 
determined whether its effect was transcriptional or post-transcriptional by simultaneously 325 
monitoring mRNA and protein abundance over time. Surface expression of PD-L1 was 326 
compared with the gene’s mRNA abundance, while the surface expression of MHCII was 327 
compared with the mRNA abundance of Ciita, the activator of MHCII expression that is initially 328 
induced by IFNg (Figure 6 A,B). In both cases, mRNA induction preceded surface expression of 329 
the respective protein. More importantly, both mRNA and protein expression of each marker was 330 
diminished to a similar degree in sgNdufa1 and sgNdufa2, compared to sgNTC cells. Thus, a 331 
deficit in transcriptional induction could account for the subsequent decrease in surface 332 
expression observed in complex I deficient cells.   333 
IFNg rapidly induces the transcription of a large number of STAT1 target genes, 334 
including IRF1, which amplifies the response. The relative impact of complex I inhibition on the 335 
immediate transcriptional response versus the subsequent IRF1-dependent amplification was 336 
initially assessed by altering the timing of complex I inhibition. As the addition of rotenone was 337 
delayed relative to IFNg stimulation, the ultimate effect on MHCII expression was diminished 338 
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(Figure 6C). If rotenone was added more than 4 hours after IFNg, negligible inhibition was 339 
observed by 24 hours, indicating that early events were preferentially impacted by rotenone. To 340 
more formally test the role of IRF1, this study was performed in macrophages harboring a 341 
CRISPR-edited Irf1 gene. While the level of MHCII induction was reduced in the absence of 342 
IRF1, the relative effect of rotenone addition over time was nearly identical in sgIrf1 and sgNTC 343 
cells.  Thus, mitochondrial function appeared to preferentially impact the initial transcriptional 344 
response to IFNg upstream of IRF1. 345 
Ligand induced assembly of the IFNGR1-IFNGR2 receptor complex results in the 346 
phosphorylation and transactivation of janus kinases 1 and 2 (JAK1, JAK2). 347 
Autophosphorylation of JAK2 at tyrosine residues 1007/1008 positively regulates this cascade 348 
and serves as a marker of JAK2 activation. These activating events at the cytoplasmic domains 349 
of the IFNGR receptor complex facilitate STAT1 docking and phosphorylation at tyrsone-701 350 
(Y701), a prerequisite for the IFNg response. Additional STAT1 phosphorylation at serine-727 351 
can amplify signaling. To determine if complex I is required for these early signal transduction 352 
events, we examined the activation kinetics by immunoblot (Figure 6D). The total abundances of 353 
IFNGR1, STAT1, and JAK2, were constant in sgNTC and sgNdufa1 cells in the presence and 354 
absence IFNg-stimulation. While we detected robust phosphorylation of JAK2 Y1007/8, STAT1-355 
Y701, and STAT1-S727 over time following IFNg treatment in sgNTC cells, phosphorylation at 356 
all three sites was both delayed and reduced across the time-course in sgNdufa1 cells. We 357 
conclude that the loss of complex I function inhibits receptor proximal signal transduction 358 
events. 359 
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 360 
Mitochondrial respiration in antigen presenting cells is required IFNg-dependent T cell 361 
activation. 362 
As respiration affected both stimulatory and inhibitory antigen presenting cell (APC) 363 
functions, we sought to understand the ultimate effect of mitochondrial function on T cell 364 
activation. To this end, we generated myeloid progenitor cell lines from Cas9-expressing 365 
transgenic mice that can be used for genome-edited and differentiated into either macrophages or 366 
dendritic cells using M-CSF or FLT3L, respectively (110, 111). Macrophages differentiated from 367 
these myeloid progenitors demonstrated robust induction of all three markers that were the basis 368 
for the IFNg stimulation screens (Supplementary Figure 2A-C). Further, both the IFNg-mediated 369 
upregulation of these markers and the inhibitory effect of rotenone or oligomycin on their 370 
induction were indistinguishable from wild-type primary bone marrow-derived macrophages 371 
(Supplementary Figure 2D-F). In both macrophages and in dendritic cells (DCs), the induction of 372 
MHCII by IFNg was inhibited by rotenone and oligomycin (Figure 7A). Unlike macrophages, 373 
murine DCs basally express MHCII and these inhibitors only repressed the further induction by 374 
IFNg (Figure 7A,B).  375 
Both macrophages and DCs were used to determine if the inhibition of complex I in 376 
APCs reduces T cell activation. Both types of APCs were stimulated with IFNg overnight with or 377 
without rotenone before washing cells to remove rotenone and ensure T cell metabolism was 378 
unperturbed. APCs were then pulsed with a peptide derived from the Mycobacterium 379 
tuberculosis protein ESAT-6, and co-cultured with ESAT-6-specific CD4+ T cells from a TCR 380 
transgenic mouse (112). T cell activation was assayed by intracellular cytokine staining for IFNg. 381 
In macrophages, T cell stimulation relied on pretreatment of the APC with IFNg, as a 382 
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macrophage line lacking the Ifngr1 gene was unable to support T cell activation. Similarly, 383 
inhibition of complex I in macrophages completely abolished antigen-specific T cell stimulation 384 
(Figure 7C). DCs did not absolutely require IFNg pretreatment to stimulate T cells, likely due to 385 
the basal expression of MHCII by these cells. Regardless, rotenone treatment of DC abrogated 386 
the IFNg-dependent increase in T cell stimulation (Figure 7C).  387 
 To confirm the effects of complex I inhibition on T cell activation using a genetic 388 
approach and confirm that complex I inhibition acted in a cell-autonomous mechanism, we 389 
generated Ndufa1 knockout myeloid progenitors (Hox-sgNdufa1). Following differentiation into 390 
macrophages, Hox-sgNdufa1 demonstrated glycolytic dependence and the inability to generate 391 
ATP by OXPHOS compared to control Hox-sgNTC macrophages (Supplementary Figure 2G). 392 
Having confirmed the expected metabolic effects of Ndufa1 loss, Hox-sgNdufa1 and Hox-393 
sgNTC macrophages were mixed at various ratios. Mixed cultures were then stimulated with 394 
IFNg, peptide pulsed, and co-cultured with antigen-specific CD4+ T cells. In agreement with our 395 
chemical inhibition studies, we found strong correlation between complex I activity in the APC 396 
population and T cell stimulatory activity (Figure 7D-E). Together, these data confirm that the 397 
IFNg-dependent augmentation of T cell stimulatory activity depends on complex I function in 398 
both macrophages and DCs.  399 
 400 
Discussion 401 
IFNg-mediated control of APC function is central to shaping a protective immune 402 
response, and the canonical IFNg signal transduction pathway has been elucidated in exquisite 403 
detail (113). Our study demonstrates that unbiased genetic analyses can reveal a multitude of 404 
unexpected cellular regulators, even for a well-characterized process such as IFNg signaling. By 405 
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independently assessing genetic determinants of stimulatory and inhibitory molecule expression, 406 
we discovered mechanisms of regulation that preferentially affect the induction of different cell 407 
surface proteins. These results begin to explain how a single cytokine can induce functionally 408 
distinct downstream responses in different contexts. These data also suggest new strategies to 409 
modulate individual co-receptors to either stimulate or inhibit T cell activation. Another strength 410 
of our parallel screen approach was the increased power to identify shared mechanisms that 411 
control IFNg-mediated regulation across all screens. Our pooled analysis identified 412 
mitochondrial respiration, and in particular complex I, as essential for IFNg-responses in APCs. 413 
We determined that complex I is required for the IFNg-mediated induction of key immune 414 
molecules and is necessary for antigen presentation and T cell activation. These findings uncover 415 
a new dependency between cellular metabolism and the immune response. 416 
Our genetic and chemical inhibition data demonstrated that mitochondrial respiration is 417 
necessary for early events in signal transduction from the IFNg receptor complex, and complex I 418 
of the respiratory chain is specifically required. While IFNg stimulation has been reported to 419 
mediate a reduction in oxygen consumption and a shift to aerobic glycolysis over time (66), the 420 
requirement of mitochondrial respiration in IFNg responses has not been assessed previously. 421 
Our results indicate that complex I is required for IFNg signaling regardless of these metabolic 422 
shifts. Complex I is a metabolic hub with several core functions that cumulatively recycle 423 
nicotinamide adenine dinucleotide (NAD+), reduce ubiquinol, and initiate the PMF for ATP 424 
generation. While any or all of these physiologic processes could contribute to IFNg signaling, 425 
the differential effects of chemical inhibitors narrow the possibilities. Both rotenone and 426 
oligomycin inhibit the IFNg response, and block electron flux through complex I either directly 427 
or indirectly. In contrast, the ionophore CCCP disrupts the PMF and ATP generation without 428 
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inhibiting electron transfer, and does not affect IFNg signaling. These data indicate that the 429 
reduction state of the quinone pool and ATP generation do not regulate IFNg responses in our 430 
system. Instead, complex I-dependent regeneration of NAD+ is the most likely regulator of IFNg 431 
signaling. Indeed, NAD+ synthesis via either the de novo or salvage pathway is necessary for a 432 
variety of macrophage functions (114-116). Very recent work demonstrates an important role for 433 
NAD+ in STAT1 activation and PD-L1 induction by IFNg in hepatocellular carcinoma cells 434 
(117).  In this setting, inhibition of NAD+ synthesis reduces the abundance of phospho-STAT1 435 
by disrupting a direct interaction with the Ten-eleven translocation methylcytosine dioxygenase 436 
1 (TET1). It remains unclear if a similar interaction occurs in the myeloid cells that are the focus 437 
of our work, as TET1 is expressed at very low levels in macrophages and splenic DC (118). 438 
Regardless, these observations indicate that both NAD+ synthesis and its regeneration via 439 
mitochondrial respiration contribute to the IFNg response in diverse cell types. This recently 440 
revealed interaction between metabolism and immunity could contribute to the observed 441 
association between NAD+ homeostasis and inflammatory diseases (116), as well as the efficacy 442 
of checkpoint inhibitor therapy for cancer (117).   443 
In the APC setting, we found that T cell activation required mitochondrial respiration. 444 
While complex I function, MHCII and CD40 expression all largely correlate with T cell 445 
stimulation, our data indicate that additional IFNg-inducible pathways also contribute to this 446 
activity. For example, unstimulated DCs basally express similar levels of MHCII as IFNg-447 
stimulated macrophages but are unable to productively present antigen to T cells. This 448 
observation suggests that additional aspects of antigen processing, presentation, or co-stimulation 449 
are IFNg- and complex I-dependent. Similarly, MHCI presentation machinery is transcriptionally 450 
induced upon IFNg stimulation (7, 119) and the induction of molecules recognized by donor 451 
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unrestricted T cells, such as MR1 and CD1, might also require additional signals to function. The 452 
specific effects of mitochondrial respiration on the type and quality of the T cell response will 453 
depend on how these diverse antigen-presenting and co-signaling molecules are influenced by 454 
cellular metabolic state.  455 
The observation that IFNg signaling depends on mitochondrial respiration provides a 456 
stark contrast to the well-established glycolytic dependency of many phagocyte functions, such 457 
as TLR signaling. This metabolic dichotomy between proinflammatory TLR signals and the 458 
IFNg response mirrors known regulatory interactions between these pathways. For example, 459 
TLR stimulation has been shown to inhibit subsequent IFNg responses, via a number of target 460 
gene-specific mechanisms (120-124). However, TLR stimulation also results in the disassembly 461 
of the ETC (123, 124), which our observations predict to inhibit STAT1 phosphorylation and 462 
IFNg signaling at the level of the receptor complex. More generally, our work suggests 463 
fundamental metabolic programs contribute to the integration of activation signals by APC and 464 
influence the ultimate priming of an immune response.  465 
 466 
Materials and Methods 467 
Cell culture 468 
Cells were cultured in Dulbecco’s Modified Eagle Medium (Gibco 11965118) supplemented 469 
with 10% fetal bovine serum (Sigma F4135), sodium pyruvate (Gibco 11360119), and HEPES 470 
(15630080). Primary bone marrow-derived macrophages (BMDMs) were generated by culturing 471 
bone marrow in the presence of media supplemented with 20% L929 supernatant for 7 days.  472 
 473 
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Immortalized macrophage cell lines in C57Bl6/J and Cas9-EGFP were established in using J2 474 
retrovirus from supernatant of CREJ2 cells as previously described(125). Briefly, isolated bone 475 
marrow was cultured in the presence of media enriched with 20% L929 supernatant. On day 3, 476 
Cells were transduced with virus and cultured with virus for 2 days. Over the next 8 weeks, L929 477 
media was gradually reduced to establish growth factor independence.  478 
 479 
Conditionally immortalized myeloid progenitor cell lines were generated by retroviral 480 
transduction using an estrogen-dependent Hoxb8 transgene as previously described(110). 481 
Briefly, mononuclear cells were purified from murine bone marrow using Ficoll-Paque Plus (GE 482 
Healthcare 17144002) and cultured in RPMI (Gibco 11875119) containing 10% fetal bovine 483 
serum (Sigma F4135), sodium pyruvate (Gibco 11360119), and HEPES (15630080), IL-6 484 
(10ng/mL; Peprotech #216-16), IL-3 (10ng/mL; Peprotech #213-13), and SCF (10ng/mL; 485 
Peprotech #250-03) for 48 hours. Non-adherent bone marrow cells from C57Bl6/J (Jax 000664), 486 
Cas9-EGFP knockin (Jax 026179), or Ifngr1 knockout (Jax 003288) mice were transduced with 487 
ER-Hoxb8 retrovirus. After transduction cells were cultured in with media supplemented with 488 
supernatant from B16 cells expressing GM-CSF and 10uM estradiol (Sigma E8875) to generate 489 
macrophage progenitor cell lines or in media supplemented with supernatant from B16 cells 490 
expressing FLT3L and 10uM estradiol (Sigma E8875) to generate dendritic cell progenitor lines. 491 
To differentiate macrophages, progenitors were harvested and washed twice with PBS to remove 492 
residual estradiol and cultured in L929 supplemented media as above. To differentiate dendritic 493 
cells(111), progenitors were harvested, washed 2x with PBS, and cultured in FLT3-enriched 494 
complete RPMI for 8-10 days.  495 
 496 
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Human monocyte-derived macrophages (MDM) were differentiated from mononuclear cells of 497 
healthy donors. Briefly, peripheral blood mononuclear cells (PBMCs) were isolated from whole 498 
blood using Ficoll-Paque-PLUS (GE Healthcare 17144002). CD14+ monocytes were purified 499 
using MojoSort™ Human CD14 Nanobeads (Biolegend 480093) according to the manufacturer's 500 
protocol. Cells were cultured in RPMI with 10% FBS, sodium pyruvate, and HEPES and 501 
supplemented with recombinant GM-CSF (50ng/mL, Peprotech 300-03) for 6 days. Thaws were 502 
harvested using Accutase (Gibco A1110501).  503 
 504 
Cell stimulations 505 
Murine IFNg (Peprotech 315-05) and human IFNg (Peprotech 300-02) were used at 10ng/mL 506 
unless otherwise indicated in the figure legends. Murine TNF (315-01A) was used at 25ng/mL. 507 
Pam3CSK4 (Invivogen tlrl-pms) was used at 200ng/mL.  508 
 509 
CRISPR screens 510 
A clonal macrophage cell line stably expressing Cas9 (L3) was established as described 511 
elsewhere(79). A plasmid library of sgRNAs targeting all protein coding genes in the mouse 512 
genome (Brie Knockout library, Addgene 73633) was packaged into lentivirus using HEK293T 513 
cells. HEK293T supernatants were collected and clarified, and virus was titered by quantitative 514 
real-time PCR and by colony counting after transduction of NIH3T3. L3 cells were transduced at 515 
a multiplicity of infection (MOI) of ~0.2 and selected with puromycin 48 hours after 516 
transduction (2.5ug/mL). The library was minimally expanded to avoid skewing mutant 517 
representation and then frozen in aliquots in freezing media (90% FBS 10% DMSO).  518 
 519 
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Two replicate screens for MHCII, CD40, and PD-L1 were performed as follows: 520 
2e8 cells of the knockout (KO) library was stimulated with IFNg (10ng/mL; Peprotech 315-05) 521 
for 24 hours after which cells were harvested by scraping to ensure integrity of cell surface 522 
proteins. Cell were stained with TruStain FcX anti-mouse CD16/32 (Biolegend 101319) and 523 
LIVE/DEAD Fixable Aqua (Invitrogen L34957) per the manufacturer's instructions. For each of 524 
the respective screens, stimulated library was stained for its respective marker with the following 525 
antibody: MHCII (APC anti-mouse I-A/I-E Antibody, Clone M5/114.15.2 Biolegend 107613), 526 
CD40 (APC anti-mouse CD40 Antibody, Clone 3/23 Biolegend 124611), or PD-L1 (APC anti-527 
mouse CD274 (B7-H1, PD-L1) Antibody, Clone 10F.9G2 Biolegend 124311). Each antibody 528 
was titrated for optimal staining using the isogenic L3 macrophage cell line. Following staining, 529 
cells were fixed in 4% paraformaldehyde. High and low expressing populations were isolated by 530 
fluorescence activated cell sorting (FACS) using a BD FACS Aria II Cell Sorter. Bin size was 531 
guided by control cells which were unstimulated and to ensure sufficient library coverage (>25x 532 
unselected library, or >2e6 cells per bin). Following isolation of sorted populations, 533 
paraformaldehyde crosslinks were reversed by incubation in proteinase K (Qiagen) at 55 degrees 534 
for 6-8 hours. Subsequently, genomic DNA was isolated using DNeasy Blood and Tissue Kit 535 
(Qiagen 69504) according to the manufacturer's instructions. Amplification of sgRNAs by PCR 536 
was performed as previously described(74, 126) using Illumina compatible primers from IDT, 537 
and amplicons were sequenced on an Illumina NextSeq500. Sequence reads were trimmed to 538 
remove adapter sequence and to adjust for staggered forward (p5) primer using Cutadapt v2.9. 539 
Raw sgRNA counts for each sorted and unsorted (input library) population was quantified using 540 
bowtie2 via MAGeCK to map reads to the sgRNA library index (no mismatch allowed); a 541 
sgRNAindex was modified to reflect genes transcribed by our macrophage cell line either basally 542 
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or upon stimulation with IFNg as previously published(79). Counts for sgRNAs were median 543 
normalized to account for variable sequencing depth.  544 
 545 
MAGeCK-MLE 546 
We used MAGeCK-MLE to test for gene enrichment. Two separate analyses were performed in 547 
order to: (1) identify regulators of the IFNg response, and (2) identify specific regulators of each 548 
of the screen targets. For both analyses, the baseline samples were the input libraries from each 549 
of the replicate screens in order to account for slight variabilities in library distribution for each 550 
screen. For (1), the generalized linear model was based on a design matrix that was "marker-551 
blind" and only considered the bin of origin (i.e. MHCII-low, CD40-low, PD-L1-low v. MHCII-552 
high, CD40-high, PD-L1-high). For (2), the design matrix was "marker-aware and bin-specific" 553 
to test for marker-specific differences (i.e. MHCII-low v. CD40-low v. PD-L1-low); the analysis 554 
was performed separately for each bin, low or high expressing mutants, to identify marker-555 
specific positive and negative regulators, respectively. For each analysis, b scores (selection co-556 
efficient) for each gene were summed across conditions to allow for simultaneous assessment of 557 
positive and negative regulators across conditions. Data are provided in Supplementary Tables.  558 
 559 
Gene-set enrichment analysis (GSEA) was performed using a ranked gene list as calculated from 560 
MAGeCK-MLE beta scores and false discovery rate (FDR). To facilitate the identification of 561 
positively and negatively enriched gene sets from the high and low expressing populations, the 562 
positive (“pos | beta”) and negative (“neg | beta”) beta scores for each gene were summed as 563 
described above (“beta_sum”). To generate a ranked gene list for GSEA, we employed 564 
Stouffer’s method to sum positive (“pos | z”) and negative (“neg | z”) selection z-scores, which 565 
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were used to re-calculate p-values (“p_sum”) as has been previously described (127-129). Using 566 
these summative metrics, we calculated a gene score as: log10(p_sum) * (beta_sum). Genes were 567 
ranked in descending order and GSEA was performed with standard settings including 568 
“weighted” enrichment statistic and “meandiv” normalization mode. Analysis was inclusive of 569 
gene sets comprising of 10-500 genes that were compiled and made available online by the 570 
Bader lab (130, 131).  571 
 572 
Plasmids and sgRNA cloning 573 
Lentivirus was generated using HEK293T cells using packaging vector psPAX2 574 
(Addgene#12260) and envelope plasmid encoding VSV-G. Transfections used TransIT-293 575 
(MirusBio MIR 2704) and plasmid ratios according to the manufacturer's instructions. For the 576 
generation of retrovirus, pCL-Eco in place of separate packaging and envelope plasmid. 577 
Retrovirus encoding the ER-Hoxb8 transgene was kindly provided by David Sykes.  578 
 579 
sgOpti was a gift from Eric Lander & David Sabatini (Addgene plasmid #85681)(132). 580 
Individual sgRNAs were cloned as previously described. Briefly, annealed oligos containing the 581 
sgRNA targeting sequence were phosphorylated and cloned into a dephosphorylated and BsmBI 582 
(New England Biolabs) digested SgOpti (Addgene#85681) which contains a modified sgRNA 583 
scaffold for improved sgRNA-Cas9 complexing. Use of sgOpti derivatives for delivery of 584 
multiple sgRNAs was performed as detailed elsewhere(79). The sgRNA targeting sequences 585 
used for cloning were as follows: 586 
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Flow cytometry 588 
Cells were harvested at the indicated times post-IFNg stimulation by scrapping to ensure intact 589 
surface proteins. Cells were pelleted and washed with PBS before staining with TruStain FcX 590 
anti-mouse CD16/32 (Biolegend 101319) or TruStain FcX anti-human (Biolegend 422301) and 591 
LIVE/DEAD Fixable Aqua (Invitrogen L34957) per the manufacturer's instructions. The 592 
following antibodies were used as indicated in the figure legends: 593 
APC-Fire750 anti-mouse I-A/I-E Antibody, Clone M5/114.15.2 Biolegend 107651 594 
PE anti-mouse CD40 Antibody, Clone 3/23 Biolegend 124609 595 
Brilliant Violet 421™  anti-mouse CD274 (B7-H1, PD-L1) Antibody, Clone 10F.9G2 Biolegend 596 
124315 597 
Alexa Fluor® 647 anti-human CD54 Antibody, Clone HCD54, Biolegned 322718 598 
PE anti-human CD40 Antibody, Clone 5C3, Biolegned 334307 599 
Brilliant Violet 421™ anti-human CD274 (B7-H1, PD-L1) Antibody, Clone 29E.2A3, Biolegend 600 
329713 601 
APC/Fire™ 750 anti-human HLA-DR Antibody, Clone L243, Biolegend 307657 602 
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 603 
For intracellular cytokine staining, cells were treated with brefeldin A (Biolegend 420601) for 5 604 
hours before harvesting. Following staining and fixation, cells were permeabilized (Biolegend 605 
421002) and stained according to the manufacturer's protocol using the following antibodies: 606 
PE anti-mouse IFN-γ Antibody, Biolegend 505807 607 
 608 
Surface protein expression was analyzed on either a MacsQuant Analyzer or Cytek Aurora. All 609 
flow cytometry analysis was done in FlowJo V10 (TreeStar).  610 
 611 
Chemical inhibitors 612 
All chemical inhibitors were used for the duration of cell stimulation unless otherwise stated. 613 
Rotenone (Sigma R8875) was resuspended in DMSO and used at 10uM unless indicated 614 
otherwise in the figure legend. Oligomycin (Cayman 11342) was resuspended in DMSO and 615 
used at 2.5uM unless otherwise indicated. CCCP (Cayman 25458) was resuspended in DMSO 616 
and used at 1.5uM unless indicated otherwise. 1400W hydrochloride (Cayman 81520) was 617 
resuspended in culture media, filter sterilized and used immediately at 25uM unless otherwise 618 
indicated. N-acetyl-L-Cysteine (NAC, Cayman 20261) was resuspended in culture media, filter 619 
sterilized and used immediately at 10mM. DMOG (Cayman 71210) was resuspended in DMSO 620 
and used at 200uM. UK5099 (Cayman 16980) was resuspended in DMSO and used at 20uM. 2-621 
deoxy-D-Glucose (2DG, Cayman 14325) was resuspended in culture media, filter sterilized and 622 
used at 1mM or at the indicated concentrations immediately. MitoTEMPO hydrate (Cayman 623 
16621) was resuspended in DMSO and used at the indicated concentrations.  624 
 625 
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For experiments that used defined minimal media with carbon supplementation, D-galactose, 626 
sodium pyruvate, and D-glucose were used at 10mM in DMEM without any carbon (Gibco 627 
A1443001). For establishment of macrophage cell line with diminished mitochondrial mass, 628 
cells were continuously cultured in linezolid (LZD) (Kind gift from Clifton Barry) for 4 weeks at 629 
50 µg/mL or DMSO control. Both LZD-conditioned and DMSO control lines were 630 
supplemented with uridine at 50 µg/mL. Prior to experimentation, cells were washed with PBS 631 
and cultured without linezolid for at least 12 hours.  632 
 633 
ELISA and nitric oxide quantification 634 
The following kits were purchased from R and D Systems or Biolegend for quantifying protein 635 
for cell supernatants: 636 
Mouse IL-6 DuoSet ELISA (DY406) or Biolegend ELISAmax (431301) 637 
Mouse TNF-alpha DuoSet ELISA (DY410) or Biolegend ELISAmax (430901) 638 
Mouse IFN-gamma DuoSet ELISA (DY485) 639 
Human IL-1 beta/IL-1F2 DuoSet ELISA (DY201) 640 
Human TNF-alpha DuoSet ELISA (DY210) 641 
Nitric oxide was quantified from cell supernatants using the Griess Reagent System according to 642 
the manufacturer’s instructions (Promega G2930). For these experiments, cell culture media 643 
without phenol red (Gibco A1443001 or Gibco 31053028).  644 
 645 
RNA isolation and quantitative real-time PCR 646 
To isolate RNA, cells were lysed in TRIzol (15596026) according to manufacturer's instructions. 647 
Chloroform was added to lysis at ratio of 200uL chloroform per 1mL TRIzol and centrifuged at 648 
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12,000 x g for 20 minutes at 4C. The aqueous layer was separated and added to equal volume of 649 
100% ethanol. RNA was isolated using the Zymo Research Direct-zol RNA extraction kit. 650 
Quantity and purity of the RNA was checked using a NanoDrop and diluted to 5ng/uL in 651 
nuclease-free water before use. Quantitative real-time PCR was performed using NEB Luna® 652 
Universal One-Step RT-qPCR Kit (E3005) or the Quantitect SYBR green RT-PCR kit (204243) 653 
according to the manufacturer's protocol and run on a Viia7 thermocycler or StepOne Plus 654 
Theromocycler. Relative gene expression was determined with ddCT method with beta-Actin 655 











Quantification of mitochondrial genomes 658 
Genomic DNA was isolated from cell pellets using the DNeasy Blood and Tissue Kit (Qiagen 659 
69504). Quantitative PCR was run using NEB Luna® Universal One-Step RT-qPCR without the 660 
RT enzyme mix and run on a Viia7 thermocycler. Relative quantification of mitochondrial 661 
genomes was determined by measuring the relative abundance of mitochondrially encoded gene 662 
Nd1 to the abundance of nuclear encoded Hk2 as has been described elsewhere(133). All primers 663 
are detailed in attached table.  664 
 665 
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At the indicated times following stimulation, cells were washed with PBS once and lysed in on 668 
ice using the following buffer: 1% Triton X-100, 150mM NaCl, 5mM KCl, 2mM MgCl2, 1mM 669 
EDTA, 0.1% SDS, 0.5% DOC, 25mM Tris-HCl, pH 7.4, with protease and phosphatase inhibitor 670 
(Sigma #11873580001 and Sigma P5726). Lysates were further homogenized using a 25g needle 671 
and cleared by centrifugation before quantification (Pierce™ BCA Protein Assay Kit, 23225). 672 
Parallel blots were run with the same samples, 15ug per well. The following antibodies were 673 
used according to the manufacturer's instructions: 674 
Purified anti-STAT1 Antibody Biolegend Clone A15158C 675 
Purified anti-STAT1 Phospho (Ser727) Antibody, Biolegend Clone A15158B 676 
Phospho-Stat1 (Tyr701) Rabbit mAb, Cell Signaling Technology Clone 58D6 677 
Jak2 XP® Rabbit mAb, Cell Signaling Technology Clone D2E12 678 
Phospho-Jak2 (Tyr1007/1008) Antibody, Cell Signaling Technology #3771S 679 
Anti-mouse β-Actin Antibody, Santa Cruz Biotechnology Clone C4 680 
Biotin anti-mouse CD119 (IFN-γ R α chain) Antibody, Biolegend Clone 2E2 681 
Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP, Invitrogen 31460 682 
Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP, Invitrogen 31430 683 
HRP-Conjugated Streptavidin, Thermo Scientific N100 684 
 685 
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Bioenergetics Assay 686 
Relative glycolytic and respiratory capacity were determined as has previously been 687 
demonstrated(134). Briefly, cellular ATP levels were determined using CellTiter-Glo® 2.0 Cell 688 
Viability Assay (Promega G9241) according to the manufacturer's protocol. Cells were grown in 689 
the conditions indicated in the figure legends for 4 hours unless stated otherwise. ATP levels 690 
were normalized according to the figure legend.  691 
 692 
T cell activation assay 693 
We used a previously established co-culture system to assess antigen presentation to Ag-specific 694 
T cells. Briefly, C7 CD4+ T cells were isolated from transgenic C7 mice, respectively and 695 
stimulated in vitro with irradiated splenocytes pulsed with the ESAT-61-15 peptide, in complete 696 
media (RPMI with 10% FBS) containing IL-2 and IL-7. After the initial stimulation, the T cells 697 
were split every two days for 3-4 divisions and rested for two to three weeks. After the initial 698 
stimulation, the cells were cultured in complete media containing IL-2 and IL-7. The following 699 
synthetic peptide epitopes were used as antigens from New England Peptide (Gardener, MA): 700 
ESAT-61-15 (MTEQQWNFAGIEAAA).  701 
For use in co-culture assay, T cells were added to peptide-pulsed macrophages as described in 702 
figure legends at an effector to target ratio of 1:1. Following 1 hours of co-culture, brefeldin A 703 
was added for 5 hours before assessing intracellular cytokine production by ICS.  704 
 705 
Quantification of subunit effects on N-module 706 
We used publicly available proteomics data in which the protein abundance of all complex I 707 
subunit was measured when each subunit was genetically deleted(93). As determined empirically 708 
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by the authors, the N-module components included: NDUFA1, NDUFA2, NDUFS1, NDUFV2, 709 
NDUFA6, NDUFS6, NDUFA7, NDUFS4, and NDUFV3. The relative effect of each subunit 710 
(using a knockout of that subunit) on N-module protein stability was calculated as the sum of the 711 
median log2 ratio of each of the above mentioned subunits, minus the median log2 ratio of itself 712 
(since it is knocked out).  713 
  714 
Statistical Analysis and Figures 715 
Statistical analysis was done using Prism Version 8 (GraphPad) as indicated in the figure 716 
legends. Data are presented, unless otherwise indicated, as the mean +/- the standard deviation. 717 
Figures were created in Prism V8 or R (Version 3.6.2). MAGeCK-MLE was used as part of 718 
MAGeCK-FLUTE package v1.8.0. 719 
  720 
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Figure Legends: 734 
Figure 1. Forward genetic screen to identify regulators of the IFNg response. A) 735 
Representative histograms of the three selected cell surface markers targeted in macrophage 736 
CRISPR screens: MHCII, CD40, and PD-L1. Blue histograms indicate expression of each 737 
marker in unstimulated macrophages and alternatively colored histograms show expression 738 
following 24 hour stimulation with recombinant murine IFNg (10ng/mL). Gates used for sorting 739 
“high” and “low” populations are shown. B) Schematic of CRISPR screens. C) Relative 740 
enrichment of select positive control (points) and all 1000 non-targeting control sgRNAs (gray 741 
distribution) are plotted as a function of their log2 fold enrichment (“high” vs “low” bins). Data 742 
are from both replicate selections for each sgRNA (sgRNA denoted by shape). D) Heatmap of b 743 
scores from CRISPR analysis, ordered according to k-means clustering (k=8) of the 5% most 744 
enriched or depleted genes in each screen. E) Macrophages were stimulated for 24 hours with 745 
TNF (25ng/mL), IFNg (10ng/mL) or both TNF and IFNg. Mean fluorescence intensity (MFI) of 746 
CD40 and MHCII were quantified by flow cytometry. Data are mean ± the standard deviation for 747 
3 biological replicates. Representative scatter plot from two independent experiments is 748 
provided. F) Macrophages transduced with sgRNA targeting Stat1, Ostc, Cnbp, or a NTC control 749 
were cultured with or without IFNg for 24 hours and cell surface expression of PD-L1 (MFI) was 750 
quantified by flow cytometry. For each genotype, data are the mean of cell lines with two 751 
independent sgRNAs ± the standard deviation. Data are representative of three independent 752 
experiments. Statistical testing in panel C was performed with Tukey’s multiple comparisons 753 
test. Within each screen, the sgRNA effects for each gene were compared to the distribution non-754 
targeting control sgRNAs. Statistical testing in panels E and F was performed by one-way 755 
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ANOVA with Holm-Sidak multiple comparisons correction. p values of 0.05, 0.01, 0.001,  and 756 
0.001are indicated by *, **, ***, and **** 757 
 758 
Figure 2. Global analysis of knockout libraries implicates mitochondrial complex I is a 759 
positive regulator of the IFNg response. A) Rank plot of the combined analysis for all genome-760 
wide knockout screens. Gene ranks (x-axis) were determined by maximal likelihood estimation 761 
(MLE). Known positive (left) and negative (right) regulators of IFNg-mediated signaling are 762 
highlighted. The q-value (false discovery rate) for each gene is indicated by dot size (-Log10 763 
FDR). B). Gene set enrichment analysis (GSEA) is based on the ranked list of positive 764 
regulators. Non-redundant pathways with a normalized enrichment score (NES) exceeding 2.0 765 
and a false discovery rate (FDR) below 0.025 are labeled. C) Relative enrichment (log2 fold 766 
change between “high” and “low” bins) of genes which comprise the mitochondrial respirasome 767 
(GeneOntology 0005746) and were targeted in the CRISPR KO library. Respirasome 768 
components are grouped by ETC complex. FDR is based on MAGeCK-MLE. D) Screen-specific 769 
enrichment score is plotted for Complex I structural subunits and assembly factors. The 770 
statistical enrichment of a gene (e.g. Ndufa1) or module (e.g. N) was calculated using a binomial 771 
distribution function to calculate the probability that observed sgRNAs under examination would 772 
be depleted or enriched given the expected median probability. P values of 0.05, 0.01, 0.001, and 773 
0.001are indicated by *, **, ***, and ****.  E) Correlation between the relative effect of each 774 
complex I subunit on the structural integrity of the N-module (x-axis) with the relative 775 
requirement of each complex I subunit for the IFNg-response (y-axis; b score, as in Panel D). 776 
The Pearson correlation coefficient (r) was calculated to be 0.6452 (95% confidence interval 777 
0.3584 to 0.8207; p-value = 0.0002. As Ndufab1 (empty square) is an essential gene, its 778 
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detection in the library indicates editing did not eliminate function; therefore, it was excluded 779 
from correlation analysis.  780 
 781 
Figure 3. Complex I is necessary for IFNg-induced MHCII and PD-L1 expression. 782 
Metabolic phenotypes in macrophage mutants were confirmed using ATP abundance following 783 
culture in media containing only (A) glucose or (B) pyruvate. Values are normalized to the 784 
average respiratory capacity of non-targeting control macrophages (NTC) and are the mean ± the 785 
standard deviation for 4 biological replicates. Statistical testing within each condition (with or 786 
without IFNg for 24h) was performed by one-way ANOVA with Dunnett’s multiple comparisons 787 
correction. (C-F) Non-targeting control (NTC), positive control (sgIfngr1 and sgPtpn2) and 788 
complex I mutant (sgNdufa1 and sgNdufa2) macrophages were stimulated for 24 hours with 789 
recombinant murine IFNg. Plotted values in C and E are the geometric mean fluorescence 790 
intensity (MFI) for a given mutant normalized to an internal control present in each well; for 791 
each gene, the data are the mean for two independent sgRNAs ± the standard deviation. 792 
Representative histograms are provided in D and F. Data are representative of >5 independent 793 
experiments. G) MHCII MFI of macrophages stimulated with IFNg and treated with rotenone at 794 
the indicated concentrations for 24 hours. Mean ± the standard deviation for 2 biological 795 
replicates are shown. Data are representative of four independent experiments.  H) Left: MHCII 796 
MFI on macrophages cultured in complete media (CM) and stimulated with IFNg and the 797 
indicated inhibitors for 24 hours. Right: MHCII MFI on macrophages cultured in CM or media 798 
containing only pyruvate (Pyr) or citrate (Cit) with or without UK5099 and stimulated with 799 
IFNg for 24 hours. Mean  ± standard deviation for 2 or 3 biological replicates is indicated. Data 800 
are representative of four independent experiments. Statistical testing was performed by one-way 801 
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ANOVA with Tukey correction for multiple hypothesis testing. p values of 0.05, 0.01, 0.001,  802 
and 0.001are indicated by *, **, ***, and ****. 803 
 804 
Figure 4. Diminished mitochondrial function specifically limits IFNg-dependent responses. 805 
A) TNF and IL-6 production by NTC or complex I mutant macrophages stimulated with 806 
Pam3CSK4 for 24 hours was determined by ELISA. Statistical testing between mutant and NTC 807 
macrophages from triplicate samples was performed by ANOVA with Dunnett’s correction for 808 
multiple comparisons. Data are representative of two independent experiments.  B) qPCR 809 
determination of relative mitochondrial genomes present per nuclear genome in macrophages 810 
cultured in vehicle (WT) or 50 ug/mL linezolid (LZD). Ct values were normalized to reference 811 
nuclear gene hexokinase 2 (Hk2) and plotted as abundance relative to WT. Data were analyzed 812 
by two-way unpaired t-test. C) ATP abundance in control or LZD-conditioned macrophages 813 
cultured in 10mM glucose, galactose or pyruvate. ATP values normalized to mean of 10mM 814 
glucose and plotted as percent. Mean ± the standard deviation for 2 biological replicates of each 815 
condition. Differences were tested by two-way ANOVA using the Sidak method to correct for 816 
multiple hypothesis testing. D) MFI of MHCII was determined by flow cytometry on control or 817 
LZD-conditioned macrophages following 24 hour stimulation with IFNg. Mean ± the standard 818 
deviation for 2 biological replicates of each condition and representative of two independent 819 
experiments. Differences were tested by two-way ANOVA using the Tukey method to correct 820 
for multiple hypothesis testing. E and F) Secretion of TNF and IL-6 in WT and LZD-conditioned 821 
macrophages following Pam3CSK4 stimulation for 6 hours was quantified by ELISA. Mean ± 822 
the standard deviation for 3 biological replicates of each condition and two independent 823 
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experiments. Data were analyzed by two-way unpaired t-test.  p values of 0.05, 0.01, 0.001,  and 824 
0.001are indicated by *, **, ***, and ****. 825 
 826 
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Figure 5. Complex I is specifically required for IFNg signaling in human cells. A) CD14+ 827 
monocytes from healthy human donors were differentiated into macrophages. MFI of cell 828 
surface markers PD-L1, ICAM1, CD40 and HLA-DR was determined by flow cytometry 829 
following stimulation with IFNg and/or inhibition of complex I with rotenone (10uM) for 24 830 
hours. Data are representative of two independent experiments and values are normalized to 831 
donor-specific unstimulated/vehicle control. Mean ± the standard deviation for 6 biological 832 
replicates of each condition. Differences were tested by two-way ANOVA using the Sidak-Holm 833 
method to correct for multiple hypothesis testing. B and C) Quantification of IL-1B and TNF 834 
production from primary human macrophages, measured by ELISA from cell supernatants 835 
following stimulation. Lines connect values for individual donors treated with vehicle (DMSO, 836 
black squares) or rotenone (empty squares). Differences were tested by repeat-measure two-way 837 
ANOVA using the Sidak-Holm method to correct for multiple hypothesis testing.  p values of 838 
0.05, 0.01, 0.001,  and 0.001are indicated by *, **, ***, and ****. 839 
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Figure 6. Complex I inhibition reduces IFNg receptor activity. A) PD-L1 transcript was 840 
quantified by qRT-PCR using DDCt relative to b-Actin in macrophages of the indicated genotype 841 
after stimulation with 10ng/mL IFNg. PD-L1 MFI was determined at the same time points by 842 
flow cytometry.  B) Ciita transcript was quantified by qRT-PCR using DDCt relative to b-Actin 843 
Gapdh in macrophages of the indicated genotype after stimulation with 10ng/mL IFNg. MHCII 844 
MFI was determined at the same time points by flow cytometry. Data shown are from biological 845 
triplicate samples with technical replicates for RT-PCR experiments and are representative of 846 
two independent experiments. C) sgNTC (left) or sgIrf1 (right) macrophages were cultured for 847 
24 hours with or without IFNg stimulation. At 2 hour intervals post-IFNg stimulation, rotenone 848 
was added. After 24 hours of stimulation, cells were harvested and surface expression of MHCII 849 
(MFI) was quantified by flow cytometry. Data are mean ± the standard deviation for 3 biological 850 
replicates and are representative of two independent experiments. Statistical testing was 851 
performed by one-way ANOVA with Tukey correction for multiple hypothesis testing.  D) 852 
Control (NTC) or sgNdufa1 macrophages were stimulated with IFNg for the indicated times, and 853 
cell lysates analyzed by immunoblot for STAT1 abundance and phosphorylation (Y701 and 854 
S727), JAK2 abundance and phosphorylation (Y1007/8), and IFNGR1. Beta-Actin was used as a 855 
loading control. Data are representative of three independent experiments. Results shown are 856 
from a single experiment analyzed on three parallel blots. p values of 0.05, 0.01, 0.001,  and 857 
0.001are indicated by *, **, ***, and ****. 858 
 859 
Figure 7. Mitochondrial respiration in antigen presenting cells is required IFNg-dependent 860 
T cell activation. A) Cell surface expression of MHCII (MFI) in macrophages (MF) or dendritic 861 
cells (DC) derived from conditionally immortalized progenitor lines. IFNg was added for 24 862 
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hours where indicated. Cells were treated with vehicle (DMSO), rotenone (10uM), oligomycin 863 
(OM, 2.5uM), or CCCP concurrent with IFNg. Data are three biological replicates and are 864 
representative of at least two independent experiments. B) Contour plot of macrophage (top row) 865 
or dendritic cell (bottom row) MHCII expression in the absence of (left column) or following 866 
(right column) stimulation with IFNg for 24 hours. Representative samples were selected from 867 
(A). The percent MHCII positive are indicated for each of the conditions. C) CD4+ T cell 868 
activation as measured by the percent of live cells positive for IFNg by intracellular cytokine 869 
staining. Prior to co-culture with T cells, APCs were stimulated with the indicated combinations 870 
of IFNg (10ng/mL), and/or rotenone (10uM) for 24 hours. After washing and pulsing with 871 
ESAT-61-15 at the indicated concentrations (nm.), T cells were added to APCs at an effector to 872 
target (E:T) ratio of 1:1, and co-cultured for a total of 5 hours. Data are representative of two 873 
independent experiments. Data are mean ± the standard deviation for 3 biological replicates. 874 
Statistical testing was performed by one-way ANOVA with Tukey correction for multiple 875 
hypothesis testing. D and E) sgNdufa1 or NTC macrophages were differentiated from 876 
immortalized progenitors, and mixed at the ratios indicated (labeled as percent of KO cells). 877 
Mixed cultures were stimulated with IFNg for 24 hours, peptide loaded, and co-cultured with 878 
CD4+ T cells (E:T 1:1). Production of IFNg was measured by ICS and quantified as the percent 879 
of cells positive for staining by flow cytometry. Representative contour plots (D) and 880 
quantification (E) of the experiment are shown. Data shown are for biological triplicate samples 881 
and are representative of two independent experiments.  p values of 0.05, 0.01, 0.001,  and 882 
0.001are indicated by *, **, ***, and ****. 883 
 884 
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 885 
Supplementary Figure Legends: 886 
Figure S1, Related to Figure 3.  A) sgNTC, sgNdufa1, sgNdufa2 cells cultured in complete 887 
media and treated with or without oligomycin (2.5µM) for 4 hours. Relative ATP levels were 888 
determined as in Figure 2A B) Intracellular ATP levels quantified as relative light units (RLU) 889 
using CellTiterGlo2.0 (Promega) for macrophages in specified growth conditions for 4 hours. 890 
Concentrations of carbon source and inhibitors are indicated in Materials and Methods. C) 891 
Macrophages were cultured in either glucose or galactose and stimulated with IFNg for 24 hours. 892 
Following stimulation, the proportion of cells with MHCII expression was determined by flow 893 
cytometry. D) Macrophages were cultured in conditions as described in Figure 4H. For each 894 
condition, cells were stimulated with IFNg or IFNg and N-acetylcysteine (NAC) for 24 hours 895 
after which cell surface levels of MHCII were quantified. E) Control or complex I mutant 896 
(sgNdufa2) macrophages were stimulated with IFNg for 24 hours with increasing doses of 897 
mitochondrial reactive oxygen species scavenger MitoTempo. For each concentration, values are 898 
plotted as a fold change relative to no scavenger; Mean ± the standard deviation for 2 biological 899 
replicates of each condition. F) Control or complex I deficient macrophages were stimulated 900 
with IFNg for 24 hours with or without the addition of DMOG or 1400W. Following stimulation, 901 
the proportion of cells with MHCII expression was determined by flow cytometry. G) Nitric 902 
oxide was measured using Griess Reagent System (Promega) from cell supernatants following 903 
stimulation with IFNg and Pam3CSK4 for 24 hours with or without the addition of DMOG or 904 
1400W. Relative nitric oxide levels were calculated as a percent relative to control (IFNg and 905 
Pam3CSK4 with DMSO). All data are representative of at least two independent experiments. 906 
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Statistical testing was performed using one-way ANOVA with Holm-Sidak multiple comparison 907 
correction. p values of 0.05, 0.01, 0.001,  and 0.001are indicated by *, **, ***, and ****. 908 
 909 
 910 
Figure S2, Related to Figure 7. A-C) Myeloid progenitors cells were conditionally 911 
immortalized by transducing murine bone marrow with an estrogen-dependent Hoxb8 transgene 912 
which maintains stem-like properties. Following differentiation of progenitors into macrophages 913 
using M-CSF enriched conditioned media, macrophages were stimulated with IFNg with or 914 
without rotenone. 24 hours after stimulation, cell surface levels of (A) MHCII, (B) CD40, (C) 915 
and PD-L1 were quantified by flow cytometry. Data are representative of 3 independent 916 
experiments and are the mean ± the standard deviation for 2 biological replicates. Statistical 917 
testing was performed by one-way ANOVA with Tukey correction for multiple hypothesis 918 
testing. D-F) As in panels A-C, macrophages from either immortalized macrophage progenitors 919 
or primary bone marrow were stimulated with IFNg with or without rotenone or oligomycin. 24 920 
hours after stimulation, cell surface levels of (D) MHCII, (E) CD40, (F) and PD-L1 were 921 
quantified by flow cytometry. G). Wild-type or DNdufa1 macrophages derived from Hoxb8-922 
immortalized bone marrow progenitors were cultured in the specified media and inhibitor 923 
condition before total intracellular ATP was quantified by CellTiterGlo2.0. For each genotype, 924 
values are relative to “glucose” control. Mean ± the standard deviation for 2 biological replicates 925 
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